
Opinion|Videos|September 10, 2024
Case Study: Diagnosing and Managing BPH in a Male Patient With Urinary Symptoms
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses how a comprehensive approach to diagnosing and managing benign prostatic hyperplasia (BPH) involves a combination of symptom assessment, lifestyle modifications, pharmacotherapy, and regular follow-up to optimize patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Patient Case Example: A man in his late 60s who presents with the following:
- History of straining to initiate and maintain a urinary stream, a weak and intermittent urinary stream, a sensation of incomplete bladder emptying after urination, and nocturia; absence of hematuria or dysuria.
- Past Medical History:
- No history of urinary tract infections or other urological conditions
- Hypertension (well-controlled with medication)
- Hyperlipidemia
- No previous surgical history
- Physical Examination:
- Digital rectal examination reveals an enlarged, nonnodular prostate (approximately 50 g); no other significant findings.
- Laboratory and Diagnostic Tests: Serum prostate-specific antigen level: 2.5 ng/mL; urinalysis: normal; uroflowmetry: peak flow rate of 8 mL/sec (borderline obstructed); post-void residual urine volume: 120 mL; transrectal ultrasound: prostate volume estimated at 55 g.
- Please describe your approach to diagnosing, treating, and managing this patient.
Advertisement
Related to this article

The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.

Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC

EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.

Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
3
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5

